PURPOSE: Aberrant activation of protein kinase Cbeta (PKCbeta) by pancreatic cancer cells facilitates angiogenesis and tumor cell survival. Targeting PKCbeta with enzastaurin, a well-tolerated drug in clinical trials, would be expected to radiosensitize pancreatic tumors through direct antitumor and antivascular effects. EXPERIMENTAL DESIGN: We tested the hypothesis that enzastaurin radiosensitizes pancreatic cancer cells in culture and in vivo through inhibition of PKCbeta. We analyzed pancreatic cancer xenografts for growth delay and microvessel density after treatment with enzastaurin, radiation, or both. We determined the effect of radiation and enzastaurin on glycogen synthase kinase 3beta, a mediator of cell death in culture and in vivo. RESULTS: At concentrations attained in patients, enzastaurin reduced levels of active PKCbeta measured by phosphorylation at Thr(500) in culture and in xenografts. Enzastaurin alone did not affect pancreatic cancer cell survival, proliferation, or xenograft growth. However, enzastaurin radiosensitized pancreatic cancer cells in culture by colony formation assay. Enzastaurin alone decreased microvessel density of pancreatic cancer xenografts without appreciable effects on tumor size. When combined with radiation, enzastaurin increased radiation-induced tumor growth delay with a corresponding decrease in microvessel density. Enzastaurin inhibited radiation-induced phosphorylation of glycogen synthase kinase 3beta at Ser(9) in pancreatic cancer cells in culture and in tumor xenografts, suggesting a possible mechanism for the observed radiosensitization. CONCLUSIONS: Enzastaurin inhibits PKCbeta in pancreatic cancer cells in culture, enhancing radiation cytotoxicity. Additional antivascular effects of enzastaurin were observed in vivo, resulting in greater radiosensitization. These results provide the rationale for a clinical trial in locally advanced pancreatic cancer combining enzastaurin with radiation.
PURPOSE: Aberrant activation of protein kinase Cbeta (PKCbeta) by pancreatic cancer cells facilitates angiogenesis and tumor cell survival. Targeting PKCbeta with enzastaurin, a well-tolerated drug in clinical trials, would be expected to radiosensitize pancreatic tumors through direct antitumor and antivascular effects. EXPERIMENTAL DESIGN: We tested the hypothesis that enzastaurin radiosensitizes pancreatic cancer cells in culture and in vivo through inhibition of PKCbeta. We analyzed pancreatic cancer xenografts for growth delay and microvessel density after treatment with enzastaurin, radiation, or both. We determined the effect of radiation and enzastaurin on glycogen synthase kinase 3beta, a mediator of cell death in culture and in vivo. RESULTS: At concentrations attained in patients, enzastaurin reduced levels of active PKCbeta measured by phosphorylation at Thr(500) in culture and in xenografts. Enzastaurin alone did not affect pancreatic cancer cell survival, proliferation, or xenograft growth. However, enzastaurin radiosensitized pancreatic cancer cells in culture by colony formation assay. Enzastaurin alone decreased microvessel density of pancreatic cancer xenografts without appreciable effects on tumor size. When combined with radiation, enzastaurin increased radiation-induced tumor growth delay with a corresponding decrease in microvessel density. Enzastaurin inhibited radiation-induced phosphorylation of glycogen synthase kinase 3beta at Ser(9) in pancreatic cancer cells in culture and in tumor xenografts, suggesting a possible mechanism for the observed radiosensitization. CONCLUSIONS:Enzastaurin inhibits PKCbeta in pancreatic cancer cells in culture, enhancing radiation cytotoxicity. Additional antivascular effects of enzastaurin were observed in vivo, resulting in greater radiosensitization. These results provide the rationale for a clinical trial in locally advanced pancreatic cancer combining enzastaurin with radiation.
Authors: Richard L Watson; Aaron C Spalding; Steven P Zielske; Meredith Morgan; Alex C Kim; Guido T Bommer; Hagit Eldar-Finkelman; Thomas Giordano; Eric R Fearon; Gary D Hammer; Theodore S Lawrence; Edgar Ben-Josef Journal: Neoplasia Date: 2010-05 Impact factor: 5.715
Authors: Christopher D Willey; Dakai Xiao; Tianxiang Tu; Kwang Woon Kim; Luigi Moretti; Kenneth J Niermann; Mohammed N Tawtawy; Chad C Quarles; Bo Lu Journal: Int J Radiat Oncol Biol Phys Date: 2009-11-10 Impact factor: 7.038
Authors: Aaron C Spalding; Benjamin D Zeitlin; Kari Wilder-Romans; Mary E Davis; Jacques E Nor; Theodore S Lawrence; Edgar Ben-Josef Journal: Transl Oncol Date: 2008-12 Impact factor: 4.243
Authors: Donald A Richards; Paul R Kuefler; Carlos Becerra; Lalan S Wilfong; Robert H Gersh; Kristi A Boehm; Feng Zhan; Lina Asmar; Scott P Myrand; Rebecca R Hozak; Luping Zhao; John F Gill; Brian P Mullaney; Coleman K Obasaju; Steven J Nicol Journal: Invest New Drugs Date: 2009-08-28 Impact factor: 3.850
Authors: Qiang Zhang; Mahaveer S Bhojani; Edgar Ben-Josef; Aaron C Spalding; Rork Kuick; Yi Sun; Meredith A Morgan Journal: J Carcinog Mutagen Date: 2013-08-16
Authors: Barbara Marengo; Chiara De Ciucis; Roberta Ricciarelli; Maria A Pronzato; Umberto M Marinari; Cinzia Domenicotti Journal: Cancers (Basel) Date: 2011-02-01 Impact factor: 6.639
Authors: Jaime Gomez-Millan; Lydia Perez; Ines Aroca; Maria Del Mar Delgado; Vanessa De Luque; Alicia Román; Esperanza Torres; Soraya Ramos; Sofia Perez; Eloisa Bayo; Jose Antonio Medina Journal: BMC Cancer Date: 2014-03-15 Impact factor: 4.430